2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2023
Significance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma
Golestani R, Singh K, Karam P, Pinto M, Liang Y, Orsaria M, Harigopal M. Significance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma. Clinical Breast Cancer 2023, 23: 91-100. DOI: 10.1016/j.clbc.2022.09.006.Peer-Reviewed Original ResearchSolid papillary carcinomaPapillary DCISInvasive carcinomaMyoepithelial cellsPapillary architecturePapillary carcinomaConventional invasive carcinomaFoci of DCISPapillary breast lesionsAssociated invasive carcinomaBreast ductal carcinomaME cellsMyoepithelial cell layerCell layerMedian followDistant metastasisHistologic evidenceDuctal carcinomaME cell layersPathology databasePapillary componentRetrospective searchResults MajorityCarcinomaDCIS
2020
High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers
Yoon EC, Wilson P, Zuo T, Pinto M, Cole K, Harigopal M. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Human Pathology 2020, 102: 13-22. PMID: 32565323, DOI: 10.1016/j.humpath.2020.06.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNon-TNBC casesFrequency of p16TNBC casesAndrogen receptorBreast cancerTissue microarrayAggressive clinical courseAndrogen receptor expressionInvasive ductal carcinomaHistologic grade 3Basal-like breast cancer subtypeNovel prognostic markerBreast cancer subtypesExpression of p16Clinical courseCytokeratin 5/6Ductal carcinomaPrognostic markerReceptor expressionRoutine biomarkersSignificant statistical differenceClinical dataGrade 3Cancer subtypes
2018
Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score
Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M. Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score. The Breast Journal 2018, 24: 976-980. PMID: 30230117, DOI: 10.1111/tbj.13117.Peer-Reviewed Original ResearchConceptsLymph node-negative patientsNode-negative patientsOncotype DX testingInvasive carcinomaLow-grade invasive carcinomasHistologic subtypeOncotype DXRecurrence scoreEstrogen receptorHigh riskAJCC Breast Cancer Staging SystemBreast cancer staging systemOncotype DX recurrence scoreFavorable histologic subtypeOncotype recurrence scoreSimple multivariable modelsCancer (AJCC) staging systemRisk of recurrenceDX recurrence scoreOnly significant predictorExcellent prognosisIntermediate riskDuctal carcinomaHistologic gradeHistologic predictors
2017
Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?
Chagpar AB, Cicek AF, Harigopal M. Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients? The American Surgeon 2017, 83: 704-708. PMID: 28738939, DOI: 10.1177/000313481708300725.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNegative marginsCancer patientsPrimary tumor markersInvasive tumor sizePrimary tumor tissuesMedian invasive tumor sizeInitial surgeryOccult cancerOccult diseaseProspective trialInitial resectionMultifocal diseasePartial mastectomyDuctal carcinomaTumor sizeCavity shavesStage 0Independent pathologistsTumor markersTissue microarrayFurther diseasePatientsTumor tissueDisease
2015
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal Of Medicine 2015, 373: 503-510. PMID: 26028131, PMCID: PMC5584380, DOI: 10.1056/nejmoa1504473.Peer-Reviewed Original ResearchConceptsCavity shave marginsPositive marginsPartial mastectomyShave marginsDuctal carcinomaBreast cancerInvasive cancerOutcome measuresStandard partial mastectomySecondary outcome measuresPrimary outcome measureLower ratesRoutine resectionMedian ageClinicopathological characteristicsCavity shavingMargin clearanceSecond surgeryInvasive carcinomaStage 0MastectomyPathological testingPatientsFurther diseaseVolume of tissue